Cytokines down‐regulated by ruxolitinib in patients with acute GVHD were mainly IL‐1, IL‐6, TNF‐α and IFN‐γ,16, 17, 18 corresponding to inflammatory effectors that mediated tissue damage and inflammation in CRS and ICANS during CAR T cell therapy. Here, TNF is linked to congenital rubella syndrome.